Article(id=1322901676834828612, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1620403200000, acceptedDateStr=2021-05-08, onlineDate=1793333938081, onlineDateStr=2026-10-30, pubDate=1626278400000, pubDateStr=2021-07-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793333938081, onlineIssueDateStr=2026-10-30, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793333938081, creator=13701087609, updateTime=1793333938081, updator=13701087609, issue=Issue{id=1322901641049015115, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='13', pageStart='1153', pageEnd='1248', issueExtLink='null', onlineDate='null', pubDate='1626278400000', pubDateStr='2021-07-15', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793333929460, creator='13701087609', updateTime=1793333989426, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322901892623376986, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322901892627571291, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1200, endPage=1206, ext={EN=ArticleExt(id=1322901680500650309, articleId=1322901676834828612, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Advances of clinical application of PARP inhibitors in ovarian cancer from pharmaceutical perspectives, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Poly ADP ribose polymerase (PARP) inhibitors are anti-tumor drugs targeting PARP enzymes. They have been approved by the US Food and Drug Administration (FDA) for the treatment of ovarian cancer, breast cancer, prostate cancer and pancreatic cancer. Additionally, National Medical Products Administration of China has also approved them for ovarian cancer. So far, PARP inhibitors have changed the traditional treatment mode for ovarian cancer. This article conducts literature review for PARP inhibitors in aspects of mechanisms of action, indications, pharmacokinetics, clinical application, and key points for pharmaceutical care, so as to provide reference to clinicians for rational use in clinical and pharmacy service for PARP inhibitors.

, authors=Yan-ting WANG¹, Yuan-yuan DAI¹, Yang-chun SUN², Guo-hui LI¹, authorsList=Yan-ting WANG, Yuan-yuan DAI, Yang-chun SUN, Guo-hui LI, authorCompany=null, correspAuthors=Guo-hui LI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322901680756502854, articleId=1322901676834828612, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=药学视角下的聚腺苷二磷酸核糖聚合酶抑制剂在卵巢癌中的应用进展, columnId=1236330553964810454, journalTitle=中国新药杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

聚腺苷二磷酸核糖聚合酶（poly ADP-ribose polymerase，PARP）抑制剂是靶向PARP酶的抗肿瘤药物，已经被美国FDA批准用于卵巢癌、乳腺癌、前列腺癌、胰腺癌的治疗；在我国也被国家药品监督管理局（NMPA）批准用于卵巢癌的治疗。PARP抑制剂在卵巢中的获批，改变了卵巢癌的传统治疗模式。本文从PARP抑制剂的作用机制、获批适应证、药动学特点、临床应用、药学服务关键点等方面对该类药物进行综述，为其合理使用及药学服务提供参考。

, authors=王燕婷¹, 戴媛媛¹, 孙阳春², 李国辉¹, authorsList=王燕婷, 戴媛媛, 孙阳春, 李国辉, authorCompany=null, correspAuthors=李国辉, authorNote=, correspAuthorsNote=, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=ImhuNaVbSpvzE83wob/0hw==, magXml=5zQEKgKbEYELsq2pG7qY7w==, pdfUrl=null, pdf=M37gguDZQkEe8dAwQ4JJnQ==, pdfFileSize=1241045, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=rPgbApU9Y5kdbrrGEHY49A==, mapNumber=null, fund=null)}, authors=[Author(id=1322901681423397198, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=phylliswang_2005@126.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901681737970000, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901681423397198, language=EN, stringName=Yan-ting WANG, firstName=Yan-ting, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901681842827601, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901681423397198, language=CN, stringName=王燕婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021, bio={"content":"

王燕婷，女，主管药师，研究方向：肿瘤临床药学。联系电话：（010）87788578，E-mail：phylliswang_2005@126.com。

"}, bioImg=null, bioContent=

王燕婷，女，主管药师，研究方向：肿瘤临床药学。联系电话：（010）87788578，E-mail：phylliswang_2005@126.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901681058492743, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=1, ext=[AuthorCompanyExt(id=1322901681066881352, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681079464265, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021)])]), Author(id=1322901682161594707, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901682291618133, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901682161594707, language=EN, stringName=Yuan-yuan DAI, firstName=Yuan-yuan, middleName=null, lastName=DAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901682656522582, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901682161594707, language=CN, stringName=戴媛媛, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901681058492743, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=1, ext=[AuthorCompanyExt(id=1322901681066881352, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681079464265, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021)])]), Author(id=1322901683025621336, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901683407303002, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901683025621336, language=EN, stringName=Yang-chun SUN, firstName=Yang-chun, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901684845949276, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901683025621336, language=CN, stringName=孙阳春, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　妇瘤科，北京　100021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901681326928202, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=2, ext=[AuthorCompanyExt(id=1322901681339511115, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681326928202, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681356288332, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681326928202, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　妇瘤科，北京　100021)])]), Author(id=1322901684946612574, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=lgh0603@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322901685097607520, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901684946612574, language=EN, stringName=Guo-hui LI, firstName=Guo-hui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901685185687905, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, authorId=1322901684946612574, language=CN, stringName=李国辉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901681058492743, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=1, ext=[AuthorCompanyExt(id=1322901681066881352, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681079464265, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021)])])], keywords=[Keyword(id=1322901685563175266, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=1, keyword=PARP inhibitors), Keyword(id=1322901685621895523, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=2, keyword=ovarian cancer), Keyword(id=1322901685689004388, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=3, keyword=mechanism of action), Keyword(id=1322901685923885413, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=4, keyword=pharmacokinetics), Keyword(id=1322901685978411366, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=5, keyword=clinical application), Keyword(id=1322901686037131623, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=EN, orderNo=6, keyword=pharmacy service), Keyword(id=1322901686112629096, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=1, keyword=PARP抑制剂), Keyword(id=1322901686179737961, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=2, keyword=卵巢癌), Keyword(id=1322901686339121514, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=3, keyword=作用机制), Keyword(id=1322901686410424683, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=4, keyword=药动学), Keyword(id=1322901686485922156, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=5, keyword=临床应用), Keyword(id=1322901686762746221, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, language=CN, orderNo=6, keyword=药学服务)], refs=[Reference(id=1322901687039570288, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075., articleTitle=null, refAbstract=null), Reference(id=1322901687177982321, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=FENG RM, ZONG YN, CAO SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1): 22., articleTitle=null, refAbstract=null), Reference(id=1322901687245091186, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=鹿欣, 姜洁, 李宁, 等. 卵巢癌PARP抑制剂临床应用指南[J]. 现代妇产科进展, 2020, 29(5): 321-328., articleTitle=null, refAbstract=null), Reference(id=1322901687324782963, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=TEWARI KS, BURGER RA, ENSERRO D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer[J]. J Clin Oncol, 2019, 37(26): 2317-2328., articleTitle=null, refAbstract=null), Reference(id=1322901687601607028, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=BANERJEE S, MOORE KN, COLOMBO N, et al. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO-1[EB/OL]. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/maintenance-olaparib-for-patients-pts-with-newly-diagnosed-advanced-ovarian-cancer-oc-and-a-brca-mutation-brcam-5-year-y-follow-up-f-u., articleTitle=null, refAbstract=null), Reference(id=1322901689275134326, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=MOORE K, COLOMBO N, SCAMBIA G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018, 379(26): 2495-2505., articleTitle=null, refAbstract=null), Reference(id=1322901689354826102, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=WU LY, ZHU JQ, YIN RT, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort[J]. Gynecol Oncol, 2021, 160(1): 175-181., articleTitle=null, refAbstract=null), Reference(id=1322901689434517879, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=RAY-COQUARD I, PAUTIER P, PIGNATA S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer[J]. N Engl J Med, 2019, 381(25): 2416-2428., articleTitle=null, refAbstract=null), Reference(id=1322901689526792568, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=POVEDA A, FLOQUET A, LEDERMANN JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation[J]. J Clin Oncol, 2020, 38(15_suppl): 6002., articleTitle=null, refAbstract=null), Reference(id=1322901689635844473, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=GONZÁLEZ-MARTÍN A, POTHURI B, VERGOTE I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2019, 381(25): 2391-2402., articleTitle=null, refAbstract=null), Reference(id=1322901689707147642, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=WU XH, ZHU JQ, YIN RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial[J]. Ann Oncol, 2021, 32(4): 512-521., articleTitle=null, refAbstract=null), Reference(id=1322901689778450811, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=MIRZA MR, MONK BJ, HERRSTEDT J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. N Engl J Med, 2016, 375(22): 2154-2164., articleTitle=null, refAbstract=null), Reference(id=1322901689853948284, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ROOS WP, THOMAS AD, KAINA B. DNA damage and the balance between survival and death in cancer biology[J]. Nat Rev Cancer, 2016, 16(1): 20-33., articleTitle=null, refAbstract=null), Reference(id=1322901689908474237, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=ASHWORTH A, LORD CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?[J]. Nat Rev Clin Oncol, 2018, 15(9): 564-576., articleTitle=null, refAbstract=null), Reference(id=1322901690118189438, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=LORD CJ, ASHWORTH A. PARP inhibitors: Synthetic lethality in the clinic[J]. Science, 2017, 355(6330): 1152-1158., articleTitle=null, refAbstract=null), Reference(id=1322901690197881215, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=狄文. PARP抑制剂卵巢癌治疗研究进展[J]. 现代妇产科进展, 2021: 1-8., articleTitle=null, refAbstract=null), Reference(id=1322901690256601472, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=KIRBY IT, COHEN MS. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics[J]. Curr Top Microbiol Immunol, 2019, 420: 211-231., articleTitle=null, refAbstract=null), Reference(id=1322901690353070465, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE. ICH harmonised guideline-biopharmaceutics classification system-based biowaivers[EB/OL]. (2019). https://database.ich.org/sites/default/files/M9_Guideline_Step4_2019_1116.pdf., articleTitle=null, refAbstract=null), Reference(id=1322901690415985026, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=EUROPEAN MEDICINES AGENCY. Zejula assessment report by Committee for Medicinal Products for Human Use[EB/OL]. (2017-09-14). https://www.ema.europa.eu/en/documents/assessment-report/zejula-epar-public-assessment-report_en.pdf., articleTitle=null, refAbstract=null), Reference(id=1322901690499871107, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=CENTER FOR DRUG EVALUATION AND RESEARCH. Clinical Pharmacology and Biopharmaceutics Review (s)[EB/OL]. (2014-02-03). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf., articleTitle=null, refAbstract=null), Reference(id=1322901690575368580, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=CLINICALTRIALS GOV. A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer[EB/OL]. (2018-10-17). https://www.clinicaltrials.gov/ct2/show/NCT03709316?term=NCT03709316&draw=2&rank=1., articleTitle=null, refAbstract=null), Reference(id=1322901690642477445, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=NATIONAL COMPREHENSIVE CANCER NETWORK. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer 2020 Version 2[EB/OL]. (2021-01-12). https://www.nccn.org/professionals/physician_gls/default.aspx., articleTitle=null, refAbstract=null), Reference(id=1322901690726363526, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=TEW WP, LACCHETTI C, ELLIS A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38(30): 3468-3493., articleTitle=null, refAbstract=null), Reference(id=1322901690797666695, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=ISON G. FDA Perspective: Evolving Development of Parp Inhibitors[EB/OL]. (2018). https://www.fda.gov/media/114655/download., articleTitle=null, refAbstract=null), Reference(id=1322901691011576200, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=PUJADE-LAURAINE E, LEDERMANN JA, SELLE F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274-1284., articleTitle=null, refAbstract=null), Reference(id=1322901691087073673, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=DOMCHEK SM, AGHAJANIAN C, SHAPIRA-FROMMER R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol, 2016, 140(2): 199-203., articleTitle=null, refAbstract=null), Reference(id=1322901691158376842, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=MOORE KN, SECORD AA, GELLER MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(5): 636-648., articleTitle=null, refAbstract=null), Reference(id=1322901691393257867, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=王燕婷, 戴媛媛, 杨珺, 等. 细胞毒化疗药物不良反应支持治疗的指南进展及实践总结[J]. 中国药学杂志, 2020, 55(20): 1726-1735., articleTitle=null, refAbstract=null), Reference(id=1322901691795911052, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=NCCN Clinical Practice Guidelines in Oncology-Antiemesis[S]. 2020: 2021., articleTitle=null, refAbstract=null), Reference(id=1322901691875602829, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=石远凯, 孙燕. 临床肿瘤内科手册[M]. 第5版. 北京: 人民卫生出版社, 2007., articleTitle=null, refAbstract=null), Reference(id=1322901692215341454, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=史艳侠, 邢镨元, 张俊, 等. 中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J]. 中国肿瘤临床, 2019, 46(17): 869-875., articleTitle=null, refAbstract=null), Reference(id=1322901693733679504, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=史艳侠, 邢镨元, 张俊, 等. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床, 2019, 46(18): 923-929., articleTitle=null, refAbstract=null), Reference(id=1322901693817565585, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=史艳侠, 邢镨元, 张俊, 等. 肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版)[J]. 中国肿瘤临床, 2019, 46(17): 876-882., articleTitle=null, refAbstract=null)], funds=[Fund(id=1322901686850826606, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, awardId=2019XK320066, language=CN, fundingSource=中国医学科学院中央级公益性科研院所基本科研业务费临床与转化医学研究基金资助项目(2019XK320066), fundOrder=null, country=null), Fund(id=1322901686922129775, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, awardId=LC2018B09, language=CN, fundingSource=中国癌症基金会北京希望马拉松专项基金青年课题(LC2018B09), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1322901681058492743, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=1, ext=[AuthorCompanyExt(id=1322901681066881352, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681079464265, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681058492743, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　药剂科，北京　100021)]), AuthorCompany(id=1322901681326928202, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, xref=2, ext=[AuthorCompanyExt(id=1322901681339511115, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681326928202, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China), AuthorCompanyExt(id=1322901681356288332, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901676834828612, companyId=1322901681326928202, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院　妇瘤科，北京　100021)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I13/1200, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I13/1200, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I13/1200, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I13/1200, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1626278400000, fullTextJson=null, articleText=null, reference=null)